Suomi - suomi - Fimea (Suomen lääkevirasto)

laboratoires thea - cefuroxime sodium - injektiokuiva-aine, liuosta varten - 50 mg - kefuroksiimi

Euroopan unioni - suomi - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatiittiautia lukuun ottamatta kortikosteroideja - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Euroopan unioni - suomi - EMA (European Medicines Agency)

sanofi winthrop industrie - lisproinsuliini - diabetes mellitus - diabeetilla käytettävät lääkkeet - diabetes mellituksen aikuisten ja lasten hoitoon, jotka tarvitsevat insuliinia normaalin glukoosin homeostaasin ylläpitoon. lisproinsuliini sanofi on myös tarkoitettu diabetes mellituksen ensimmäiseen stabilointiin.

Euroopan unioni - suomi - EMA (European Medicines Agency)

alnylam netherlands b.v. - patisiran natrium - amyloidoosi, perinnöllinen - muut hermoston huumeet - onpattro on tarkoitettu hoitoon perinnöllinen transthyretin-välitteisen amyloidoosi (hattr amyloidoosi) aikuisilla potilailla, joilla on vaiheen 1 tai vaiheen 2 polyneuropatia.

Euroopan unioni - suomi - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - - rokotteet - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 ja 4. käyttö dengvaxia pitäisi olla virallisten suositusten mukaisesti.

Euroopan unioni - suomi - EMA (European Medicines Agency)

alnylam netherlands b.v. - givosiran - porphyrias, maksan - muut ruuansulatuselimistön sairauksien ja aineenvaihduntasairauksien lääkkeet - akuutin maksan porfyria (ahp) aikuisille ja nuorille vuotiaiden 12 vuotiaat ja vanhemmat.

Euroopan unioni - suomi - EMA (European Medicines Agency)

sanofi winthrop industrie - insuliini aspart - diabetes mellitus - diabeetilla käytettävät lääkkeet - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Euroopan unioni - suomi - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - multiple myeloma - antineoplastiset aineet - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Euroopan unioni - suomi - EMA (European Medicines Agency)

blueprint medicines (netherlands) b.v. - avapritinib - ruoansulatuskanavan stromal-kasvaimet - muut antineoplastiset aineet, proteiinikinaasin estäjät - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Euroopan unioni - suomi - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - niveltulehdus, nivelreuma - immunosuppressantit - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.